Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANGIODYNAMICS INC (ANGO)

AngioDynamics Q1 sales rise 6.9% to $80.9 million; net loss narrows, new CEO named

Positive Impact 4 of 5 earnings Written later

AngioDynamics reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9%, and a GAAP net loss of $7.1 million, or $0.17 per share, versus a loss of $10.9 million a year earlier. The company also said Eric Honroth will succeed Jim Clemmer as President and CEO on November 2, 2026, and reiterated its fiscal 2027 guidance, which matters to shareholders because it signals continuity in results and a planned leadership change.

Key points

  • Net sales were $80.9 million, up 6.9%; Med Tech sales rose 13.2% to $39.9 million while Med Device sales rose 1.4% to $41.0 million.
  • GAAP net loss narrowed to $7.1 million, or $0.17 per share, from $10.9 million, or $0.26 per share, a year earlier.
  • Adjusted EBITDA was $5.0 million versus $2.2 million; gross margin was 59.4%, including $1.2 million of tariff refunds.
  • Eric Honroth becomes CEO effective November 2, 2026, succeeding Jim Clemmer; fiscal 2027 net sales guidance of $336.0 million to $341.0 million was reiterated.

The filing

CompanyANGIODYNAMICS INC (ANGO)
Form8-K, current report
Filed with the SECOct 8, 2026, 7:17 AM ET
Accession number0001140361-26-039020

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.